![MARINOMED BIOTECH AG [CBOE]](/medias/logo_company/9MZxl4ODHOG55H2.png "MARINOMED BIOTECH AG [CBOE]"){kind=logo}
MARINOMED BIOTECH AG [CBOE] news, videos and press releases
For more news please use our advanced search feature.
MARINOMED BIOTECH AG [CBOE] - More news...
MARINOMED BIOTECH AG [CBOE] - More news...
- EQS-AGM: Marinomed Biotech AG: Invitation to the 7th Annual General Meeting on Thursday, June 20, 2024, at 13:00 (Vienna time)
- EQS-News: Marinomed Biotech AG announces results for the first quarter of 2024
- EQS-News: Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios
- EQS-News: Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets
- EQS-News: Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico
- EQS-News: Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months
- EQS-News: Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe
- EQS-News: Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public Relations
- EQS-News: Marinomed Biotech AG announces preliminary revenue for 2023
- EQS-News: Marinomed Biotech AG with important progress for Carragelose in 2024
- EQS-News: Marinomed Biotech AG evaluates strategic options for Carragelose portfolio
- EQS-Adhoc: Marinomed Biotech AG evaluates strategic options for Carragelose portfolio
- EQS-News: Marinomed Biotech AG with new Carragelose distribution and manufacturing partners and EU patent
- EQS-News: Marinomed Biotech AG: Stable revenues in the first three quarters of 2023 and further progress in business development
- EQS-News: Marinomed Biotech AG resumes Nice & Green Convertible Notes Funding Program with reduced volume
- EQS-News: Marinomed Biotech AG reports record revenues in the first half of the year and pushes business development activities
- EQS-News: Marinomed enters first long-term Solv4U partnership with Shanghaibased SPH Sine Pharmaceutical Laboratories Co. Ltd.
- EQS-News: Marinomed Biotech AG: M8 Pharmaceuticals obtains market authorization for Carragelose nasal spray in Mexico
- EQS-News: Peer-reviewed publication by Marinomed Biotech AG and Friedrich-Alexander-University Erlangen-Nürnberg reconfirms broad virus-blocking effectiveness of iota-carrageenan
- EQS-News: Marinomed Biotech AG: Annual General Meeting elects Dr. Eva Hofstädter-Thalmann as a new member of the Supervisory Board
- EQS-News: Marinomed Biotech AG prepares launch of Carragelose eye drops in 2024
- EQS-News: Marinomed Biotech AG reports best first quarter in company history
- EQS-News: Marinomed Biotech AG with Carragelose record sales in 2022 and positive outlook for 2023
- EQS-News: Marinomed Biotech AG publishes clinical data on the effectiveness of its Carragelose nasal spray in the treatment of hay fever
- EQS-News: Marinomed Biotech AG reports positive clinical data for the Carragelose decongestant nasal spray
- EQS-News: Marinomed Biotech AG announces preliminary revenue for 2022 with double-digit growth for Carragelose
- EQS-News: Marinomed Biotech AG: Marinomed Biotech receives US Patent approval for the Marinosolv® technology and invests in a series of new patents
- EQS-News: Marinomed Biotech AG reports increase in revenues for the first 9 months 2022 and significant business development progress
- EQS-News: First successful year on the market for Marinomed’s Solv4U technology partnerships
- DGAP-News: Marinomed to attend several upcoming investor and industry conferences
